REDUCE-1 Pilot: Restrictive Fluids Safe But Failed Feasibility in PICU

This pilot trial informs how ICU pharmacists should approach fluid stewardship in ventilated children, showing a pragmatic restrictive bundle is safe but too weakly separated from usual care to justify a full trial as designed.

restrictive fluid strategyintravenous fluidsfluid overloadpediatric critical carePICUmechanical ventilationREDUCE-1pilot RCTvasoactive-inotrope scoreacute kidney injuryfeasibility trial Critical Care / ICU

Background Information

Can restrictive fluid protocols improve outcomes in PICU patients?

Fluid management in pediatric intensive care unit (PICU) patients is crucial due to the risks associated with fluid overload, impacting outcomes. The study demonstrated that a restrictive intravenous (IV) fluid strategy did not achieve a significant difference in fluid balance compared to usual care in mechanically ventilated children. The REDUCE-1 restrictive fluid protocol as tested in this pilot study is not feasible for a full trial, hence future studies need refined protocols. Restrictive fluid management in PICU requires further refinement for feasibility.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Raman S, Rahiman S, Kennedy M, Kühlwein E, Le Marsney R, Mattke AC, McBride CA, Tu Q, Venugopal P, Woodgate J, Zapf F, Singh P, Schlapbach LJ, Gibbons KS

Citation: Raman S, Rahiman S, Kennedy M, et al. Restrictive Vs. Standard Fluid Management in Mechanically Ventilated Children Admitted to PICU: A Pilot Randomized Controlled Trial. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2026. doi:10.1097/PCC.0000000000003969

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →